AMG 510

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

16 competitors in Lung Carcinoma

#DrugCompanyPhaseTrials

1

Lumakras

Amgen

Approved

12

Afinitor

Novartis

Approved

—3

Iressa

AstraZeneca

Approved

—4

Aurlumyn

BBTG International Inc.

Approved

—5

Chantix

PPrism Pharmaceuticals

Approved

—6

Navelbine

PPierre Fabre Medicament

Approved

—7

Leukine

Sanofi

Phase 2

18

Vectibix

Amgen

Preclinical

19

Nicorette

Pfizer

Preclinical

—10

Nicotine Replacement

GSK

Preclinical

1Show 6 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Lung Cancer1 trial

A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05118854·13 enrolled

Small Cell Lung Cancer1 trial

A Multicenter, Open-label, Single-arm, Expanded Access Protocol of Sotorasib for the Treatment of Subjects With Previously Treated Locally Advanced Unresectable/Metastatic NSCLC With KRAS p.G12C Mutation

No longer available·Amgen··NCT04667234

KRAS p, G12c Mutated /Advanced Metastatic NSCLC1 trial

A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

Completed·Amgen·Phase 3·NCT04303780·345 enrolled

Details

Drug Info

Related News